SCHEMBL2474155

SCHEMBL2474155

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CCCN2CCOCC2)NC(=O)Nc2ccc3ncccc3c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.42
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TACR2 P21452 1/20 0.40
POLB P06746 1/20 0.40
PABPC1 P11940 1/20 0.39
HDAC1 Q13547 1/20 0.39
EPHX2 P34913 3/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
ADRA1D P25100 1/20 0.38
HTR2A P28223 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
ADRA1B P35368 1/20 0.38
DRD3 P35462 1/20 0.38
KCNH2 Q12809 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3829052 0.88 HDAC1 (0.50) TACR2PABPC1HDAC1JAK2
SCHEMBL2474232 0.86 NAMPT (0.47) CD274NPC1RAB9APOLBEPHX2
SCHEMBL2477762 0.83 CD274 (0.45) CD274RAB9ATACR2POLBEPHX2
SCHEMBL2477555 0.83 CD274 (0.47) CD274TACR2EPHX2ABCB1ABCG2
SCHEMBL2477400 0.83 CYP2D6 (0.48) CD274NPC1RAB9APOLBCASR
SCHEMBL3835932 0.82 USP2 (0.48) CD274NAMPTCASR
SCHEMBL3235294 0.80 CASR (0.44) CD274POLBEPHX2CASR
SCHEMBL10476433 0.80 CD274 (0.46) CD274TACR2POLBEPHX2JAK2
SCHEMBL3232291 0.80 EPHX2 (0.47) CD274POLBEPHX2JAK2NAMPT
SCHEMBL4219747 0.80 CD274 (0.41) CD274TACR2POLBEPHX2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 CD274 4808/4885NPC1 989/4885RAB9A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.